GSK-5959, 98%, a potent, selective and cell permeable BRPF1 bromodomain inhibitor

Name: GSK-5959, 98%, a potent, selective and cell permeable BRPF1 bromodomain inhibitor | 901245-65-6
Brand: J&K Chemical
SKU: JK1866805_5_MG
Price: 127.6 USD
Availability: OutOfStock

Cat. No JK1866805_5_MG

Vendor: J&K Chemical

Product Information

Product Name

GSK-5959, 98%, a potent, selective and cell permeable BRPF1 bromodomain inhibitor

Brand Name

J&K

Product Number

1866805

CAS

901245-65-6

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

15990224

IUPAC Name

N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide

InChI Key

LTUGYAOMCKNTGG-UHFFFAOYSA-N

SMILES

CN1C2=C(C=C(C(=C2)NC(=O)C3=CC=CC=C3OC)N4CCCCC4)N(C1=O)C

Safety Information

Storage Condition

Freezer -20℃

References

Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2023-08-08

DOI: 10.1021/acs.jmedchem.3c00671

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Publication Name: Science Translational Medicine

Publication Date: 2023-06-21

DOI: 10.1126/scitranslmed.add7872

Target Class Profiling of Small-Molecule Methyltransferases

Publication Name: ACS Chemical Biology

Publication Date: 2023-03-28

DOI: 10.1021/acschembio.3c00124

Discovery of Potent Small-Molecule SIRT6 Activators: Structure–Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2020-08-12

DOI: 10.1021/acs.jmedchem.0c01183

High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway in Skeletal Muscle

Publication Name: ACS Chemical Biology

Publication Date: 2020-05-27

DOI: 10.1021/acschembio.0c00343

GSK-5959, 98%, a potent, selective and cell permeable BRPF1 bromodomain inhibitor

Product Information

General Information

Safety Information

References

Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Target Class Profiling of Small-Molecule Methyltransferases

Discovery of Potent Small-Molecule SIRT6 Activators: Structure–Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity

High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway in Skeletal Muscle